Knowledge HQ

This phase 2 trial evaluates virus-specific T cells (VSTs) for treating BK polyomavirus in transplant recipients. Manufactured in G-Rex devices, donor-derived and third-party VSTs demonstrated high response rates for viremia and hemorrhagic cystitis with minimal toxicity, offering a safe therapy for BKPyV.

This study assesses the safety of piggyBac transposon-mediated hGMR-CAR T cells in a non-human primate model. Using G-Rex for expansion, researchers generated autologous CAR T cells that showed potent killing in vitro and no overt toxicity in vivo, supporting the safety of this approach for clinical trials.

This study introduces T-CEP, a soluble activator for T cell expansion. G-Rex 24-well plates were used for the 12-day expansion period. T-CEP stimulation favored the growth of CD8+CD27+ T cells, a phenotype associated with better persistence and clinical outcomes.

This review describes the AIM platform, which uses nanoparticle-based artificial APCs to generate antigen-specific T cells. The enrichment and expansion (E+E) process, utilizing G-Rex culture systems, produces consistent, high-quality memory CD8+ T cells for clinical adoptive cell therapy applications.

This book chapter details the use of G-Rex technology for large-scale cell expansion. It covers protocols for G-Rex plates and closed systems, optimization of seeding and feeding, and harvesting. It highlights the linear scalability of the platform for CAR-T and NK cell production.

Describes a manufacturing process for HIV Gag-specific CD4 T cells modified with AGT103 lentivirus. The process was improved by combining CliniMACS Prodigy with static culture in G-Rex 500M-CS vessels, significantly increasing cell expansion and yield compared to the automated system alone.

The authors used a high-throughput assay to optimize cytokine conditions for VST expansion. Results showed IL-15/IL-6 was effective. These findings were validated by scaling up cultures in G-Rex 10 devices, which produced functional T cells equivalent to standard protocols.

This review discusses establishing academic GMP facilities for cell therapy. It highlights the use of closed systems like G-Rex (referenced via Harari et al.) to improve efficiency and compliance. The article emphasizes the benefits of hospital-based manufacturing for personalized therapies like TILs.

Abstract describing the preclinical validation of IL-8 receptor-modified CD70 CAR T cells. The G-Rex system was used for ex vivo expansion, achieving approximately 1200-fold expansion in 2 weeks. The optimized process allows for clinical scale production using small blood volumes.

The authors developed the QuIK assay to measure proliferation and killing kinetics of engineered T cells. Primary human T cells were transduced and expanded in 24-well G-Rex plates. The assay provides detailed insights into the functional biology of CAR-T and TCR-T cells over time.

This research demonstrates that photodepletion with 2-Se-Cl selectively removes alloreactive T cells to prevent GVHD without compromising antitumor immunity. G-Rex devices were utilized for the initial co-culture and priming of splenocytes before the photodepletion step.

This study characterizes CMV-specific T lymphocytes (VSTs) expanded rapidly for adoptive immunotherapy. Using G-Rex technology with IL-2, IL-7, and IL-15, researchers achieved a scalable process yielding functional, cytotoxic T cells. The method ensures high specificity and safety for treating viral infections.